【Dictation】听写第五天

挫败感会伴随一系列负面情绪，产生的缘由是，你比不上别人，你没有什么所获。

于是你打不起精神，做事没动力，效率不高，想追求却又不敢，心生忧郁和自卑。

这是一套负反馈系统。

不够好又怎地？最好的只有一个，就算不是太好，掖能过得不差。

把价值评判系统让渡给别人掌控，你的人生还算个毛线？

屌丝耐操，才有机会。

别吭声，抱怨没有用，哭泣没有用，悲伤没有用，悲哀没有用。

这些只能消减你的力量，最终还是滑向深渊。

你应该耐心好好积累，什么话都别说。

加油！

Test Cancer Drugs Against Its Spread

A cancer expert argues that our current system for testing drugs fails to fully examine those that might stop metastasis. Cynthia Graber reports.

June 1, 2012

The biggest risk for breast cancer patients is usually not original tumor, which is removed by surgery. The cancer becomes particularly deadly if it metastasizes and forms tumors elsewhere in the body.

But drugs to target the metastatic process would fail the current clinical-trial system for breast cancer treatments.

Patricia Steeg is the chief of the Women’s Cancers Section at the National Cancer Institute. She argues in the journal Nature that a new approach is needed in testing and approving breast cancer drugs. [Patricia S. Steeg, Perspective: The right trials]

New breast cancer drugs today must demonstrate that they shrink established tumors. But a beneficial drug might not reduce the size of a tumor. Instead, it might fight metastasis in a number of ways—it could kill keep cells from escaping the tumor, or kill them in the bloodstream.

Steeg argues that the FDA needs to change the model, and that anti-metastasis drugs should be tested in combination with current therapies. The success should not be related only to shrinking tumors, but rather to preventing new tumors from forming. She says this approach will help not only breast cancer patients, but millions of survivors in remission who worry that a new tumor will appear.

—Cynthia Graber

[The above text is a transcript of this podcast]